Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus

8 Mar 2018

Abstract excerpt

Naturally occurring, large deletions in the β-globin locus result in hereditary persistence of fetal hemoglobin, a condition that mitigates the clinical severity of sickle cell disease (SCD) and β-thalassemia. We designed a clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) (CRISPR/Cas9) strategy to disrupt a 13.6-kb genomic region encompassing the δ- and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemoglobinopathies and Related Disorders
Share to Iron Metabolism and Disorders
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29519807
DOI: 10.1182/blood-2017-10-811505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locusPMID 29519807Read ↗

A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.Semantic proximity Read ↗

CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell diseaseSemantic proximity Read ↗

Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.Semantic proximity Read ↗

CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cellsSemantic proximity Read ↗

Using Clustered Regularly Interspaced Short Palindromic Repeats gene editing to induce permanent expression of fetal hemoglobin in β-thalassemia and sickle cell disease: A comparative meta-analysisSemantic proximity Read ↗

CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cellsSemantic proximity Read ↗

CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell DiseaseSemantic proximity Read ↗

Combined approaches for increasing fetal hemoglobin (HbF) and de novo production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients: treatment with HbF inducers and CRISPR-Cas9 based genome editingSemantic proximity Read ↗

Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responsesSemantic proximity Read ↗

Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.Semantic proximity Read ↗

A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 siteSemantic proximity Read ↗

Elevating fetal hemoglobin: recently discovered regulators and mechanismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.